Therapeutics News and Research

RSS

Discovery of first gender-linked susceptibility gene for late-onset Alzheimer's disease

In the Jan. 11 online edition of Nature Genetics, they report the results of their two-stage genome-wide association study of patients with Alzheimer's disease. The research showed that women who inherited two copies of a variant in the PCDH11X gene, found on the X chromosome, are at considerably greater risk of developing Alzheimer's disease.

12 Jan 2009

FORMA Therapeutics to collaborate with Novartis on inhibitors

FORMA Therapeutics has announced that it has entered into a license and option agreement through the Novartis Option Fund.

12 Jan 2009

New drugs have longer clinical development times despite faster FDA review

While the U.S. Food and Drug Administration Drug has quickened review and approval of new medicines, the complex nature of diseases for which new therapeutics are being developed has resulted in longer clinical development times, according to the Tufts Center for the Study of Drug Development.

8 Jan 2009

Liquidia Technologies to collaborate with Abbott on siRNA therapeutics

Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

7 Jan 2009

Chimerix completes phase I study and starts phase II multi-dose trial for CMX001

Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, has announced that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers.

6 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009

Laminin-111 shows potential for congenital muscular dystrophy

Current research suggests laminin, a protein that helps cells stick together, may lead to enhanced muscle repair in muscular dystrophy.

1 Jan 2009

Medication errors among adults and children with cancer in the outpatient setting common

Seven percent of adults and 19 percent of children taking chemotherapy drugs in outpatient clinics or at home were given the wrong dose or experienced other mistakes involving their medications, according to a new study supported in part by HHS' Agency for Healthcare Research and Quality through its Centers for Education and Research on Therapeutics program.

1 Jan 2009

VistaGen, WARF sign license agreement for human embryonic stem cell technology

VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools.

18 Dec 2008

Prozac enhances effectiveness of anti-cancer drug

Prozac is regularly prescribed to ease the emotional pain of patients who are being treated for cancer.

18 Dec 2008

Levels of two proteins impact survival in ovarian cancer

Levels of two proteins in a woman's ovarian cancer are strongly associated with her likelihood of survival, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Dec. 18 issue of the New England Journal of Medicine.

17 Dec 2008

Abbott starts trial of 2.25 mm stent system

Abbott has announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V Everolimus Eluting Coronary Stent System.

17 Dec 2008

Researchers find brain's reward and stress signaling circuits are intertwined in complex ways

Vanderbilt University Medical Center investigators have now discovered a functional link between reward and stress. They found that dopamine - the brain's chief reward signal - works through corticotrophin-releasing factor (CRF) - the brain's main stress signal - to increase the activity of a brain region involved in addiction relapse.

16 Dec 2008

Discovery of new way a man can transmit the HIV virus to a woman

Scientists had long believed that the normal lining of the female vaginal tract was an effective barrier to invasion of the HIV virus during sexual intercourse. They thought the large HIV virus couldn't penetrate the tissue.

16 Dec 2008

Trans-splicing therapy for spinal muscular atrophy closer to clinical use

Spinal muscular atrophy, a neurodegenerative disorder that causes the weakening of muscles, is the leading cause of infant death and occurs in 1 in 6,000 live births.

16 Dec 2008

Mucosal lining of the female genital tract no barrier to HIV sexual transmission

Contrary to a widely-held assumption about heterosexual transmission of HIV, the normal mucosal lining of the female genital tract is not a foolproof barrier to viral penetration, scientists at the Northwestern University School of Medicine in Chicago report at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

16 Dec 2008

Alzheimer's researcher explores the variety of animal models now being used in research

Very few species spontaneously develop the cognitive, behavioral and neuropathological symptoms of Alzheimer's disease (AD), yet AD research must progress at a more rapid pace than the rate of human aging.

15 Dec 2008

Gene therapy used to treat periodontal disease

Scientists at the University of Michigan have shown that gene therapy can be used to successfully stop the development of periodontal disease, the leading cause of tooth loss in adults.

12 Dec 2008

Pralatrexate shows promise for T-Cell lymphoma

Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).

10 Dec 2008